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Background-—Fibroblast growth factor–23 (FGF-23) is a phosphaturic factor previously associated with left ventricular hypertrophy
and systolic dysfunction among individuals with chronic kidney disease. Whether FGF-23 acts directly to induce left ventricular
hypertrophy, potentially independent of its klotho coreceptor, remains uncertain. We investigated associations of FGF-23 with
cardiac structural abnormalities among individuals with a broad range of kidney function and explored potential biological
mechanisms using cardiac magnetic resonance imaging and histology in klotho-null mice, an established model of constitutively
elevated FGF-23.
Methods and Results-—Among 887 participants with coronary artery disease in the Heart and Soul Study, FGF-23 was modestly
associated with worse left ventricular ejection fraction (1.0% per standard deviation increase in lnFGF-23; standard error, 0.4%),
but was not associated with the overall prevalence of concentric hypertrophy (odds ratio, 1.5; CI, 0.9 to 2.4) or eccentric
hypertrophy (odds ratio, 1.1; CI, 0.9 to 1.3). FGF-23 was only associated with concentric hypertrophy among individuals with
diminished kidney function (eGFR <60 mL/min per 1.73 m
2; odds ratio, 2.3; CI, 1.0 to 5.3; P-interaction=0.28). Comparing klotho-
null with wild-type mice, null mice did not have greater left ventricular mass (P=0.37) or a lower ejection fraction (P=0.94).
Conclusions-—Together, our results suggest that FGF-23 is unlikely to have major effects on cardiovascular structure and
function among patients free of substantial chronic kidney disease, and these effects may not be independent of the klotho
coreceptor. (J Am Heart Assoc. 2014;3:000584 doi: 10.1161/JAHA.113.000584)
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F
ibroblast growth factor–23 (FGF-23) is a circulating
hormone secreted primarily by osteocytes. In the renal
tubules, FGF-23 binds to the FGF receptor 1c and the klotho
coreceptor to promote phosphaturia and lower circulating
levels of 1,25-dihydroxyvitamin D.
1 Circulating levels of
FGF-23 can rise 100- to 1000-fold in patients with a
diminished capacity for phosphorous excretion, such as those
with chronic kidney disease (CKD).
2 In patients with CKD,
supraphysiologic levels of FGF-23 are strongly associated with
left ventricular mass index (LVMI), left ventricular hypertrophy
(LVH), cardiovascular events, and mortality.
3–5 Recently,
these ﬁndings have also been variably extended to individuals
with intact renal function,
6–8 but associations have not been
consistent throughout the population.
6,9
Given these inconsistencies, one of the key open questions
that remains in the ﬁeld is whether the association between
FGF-23 and LVH is likely to be causal.
10 Several studies have
failed to replicate associations of FGF-23 and LVMI,
11 and
others have suggested that associations with cardiovascular
disease may be context dependent, manifesting primarily
among individuals with renal tubular dysfunction.
9 If the latter
is true, FGF-23 could simply be a biomarker of underlying
kidney damage among individuals with CKD, rather than being
directly toxic to the cardiovascular system.
10
To address this question, several research groups have
investigated whether FGF-23 has direct effects on cardiac
myocytes in experimental models, but again results have been
inconsistent.
12–14 In 1 study, a 5/6-nephrectomized rat model
of CKD developed LVH that was signiﬁcantly attenuated with
administration of the FGF receptor antagonist PD-173074.
12
However, an FGF-23-neutralizing antibody did not reduce the
hypertrophy in another investigation using the same animal
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13 In a third study, a Col4a3
/ mouse model of CKD
with elevated FGF-23 demonstrated increased gene expres-
sion of markers of pathological hypertrophy but no increase in
cardiomyocyte size or ventricular wall thickness.
14 The
possibility of a klotho-independent direct effect of FGF-23
on cardiomyocytes has been raised by the observation that
klotho-deﬁcient mice, an established animal model of consti-
tutively elevated FGF-23, develop echocardiographic LVH.
12
This latter ﬁnding has not yet been widely replicated or tested
in the context of other imaging modalities.
We investigated the relationships between FGF-23, left
ventricular mass, structure, and systolic function among
patients in the Heart and Soul Study, a well-characterized
cohort of patients with stable coronary heart disease and a
broad range of kidney function. We also explored the
putative effects of FGF-23 activity in homozygous and
heterozygous klotho-deﬁcient mice using cardiac magnetic
resonance imaging (MRI), a potentially more accurate
method to quantify LVH than the echocardiography used
previously. Together, our population and mouse results raise
questions about the generalizability of the effect of FGF-23
on cardiac structure.
Methods
Participants
The Heart and Soul Study is a longitudinal cohort study
designed to investigate the relationship of psychosocial
stressors and cardiovascular disease progression. Study
methods have been described in detail elsewhere.
15 Brieﬂy,
inclusion required ≥1 of the following: history of myocardial
infarction, angiographic evidence of >50% stenosis in ≥1
coronary vessel, evidence of exercise-induced ischemia by
treadmill or nuclear testing, history of coronary revasculari-
zation, or documented diagnosis of coronary artery disease.
Individuals were excluded if they were unable to walk 1 block,
survived a myocardial infarction within the past 6 months, or
planned to move out of the area within 3 years. The
institutional review boards of all participating institutions
approved the study protocol, and all study participants
provided written informed consent.
Between September 2000 and December 2002, 1024
participants from 12 outpatient clinics in the San Francisco
Bay area were enrolled. In primary analyses, we excluded 11
individuals (1.1%) with missing values of echocardiographic
data, 34 individuals (3.3%) with missing values of FGF-23, and
92 individuals (9.0%) with missing values of other demo-
graphic or clinical measurements, resulting in a ﬁnal sample
size of 887 participants. We performed sensitivity analyses
using multiple imputation with the Markov Chain Monte Carlo
method and 10 imputations to include all individuals, which
produced essentially identical results as the complete case
approach.
Exposure and Outcome Assessment
We obtained serum and plasma samples from all participants
at their baseline visit after a 12-hour fast. FGF-23 was
measured in duplicate (and averaged) from frozen samples in
2007 using a carboxy-terminal human enzyme-linked immu-
nosorbent assay (Immutopics).
16 The intra-assay coefﬁcient of
variation was 5.0%; the interassay coefﬁcient of variation was
9.9% at a concentration of 36.4 RU/mL and 12.6% at a
concentration of 379 RU/mL.
7
Participants underwent a complete 2-dimensional echo-
cardiogram at baseline. We obtained standard 2-dimensional
parasternal short axis and apical 2- and 4-chamber views
during suspended inspiration. A cardiologist blinded to all
other clinical information interpreted the echocardiograms.
We determined left ventricular mass on the basis of wall
thickness measurements using a truncated ellipsoid tech-
nique and indexed results to body surface area to generate
LVMI.
17 We evaluated whether associations with LVMI were
sensitive to further adjustment by body mass index (BMI). We
considered participants who had LVMI >90 g/m
2 to have
LVH.
18 We calculated relative wall thickness as: (posterior
wall thickness+septal wall thickness)/end-diastolic cavity
dimension.
17 We further categorized LVH into mutually
exclusive categories of eccentric and concentric LVH. We
classiﬁed LVH as eccentric if relative wall thickness was
≤0.43 and concentric if relative wall thickness was >0.43.
Because concentric and eccentric LVH result from different
modes of cardiomyocyte growth, differences in their respec-
tive associations with FGF-23 may provide insight about the
underlying mechanism of FGF-23 activity in the heart. We
determined LVEF by the American Society of Echocardiogra-
phy recommended biplane method of disks.
19
Ascertainment of Demographic and Clinical Data
At baseline, participants reported age, sex, ethnicity,
prevalent hypertension and diabetes, current smoking status,
smoking history (used to calculate pack-years of smoking),
and level of physical activity (relative to others of the same
age and sex) by questionnaire. Trained study personnel
measured weight and height (used to calculate BMI) and
measured blood pressure after 5 minutes of rest in the supine
position. We measured total cholesterol, high-density lipopro-
tein cholesterol, triglycerides, serum phosphorous, and serum
calcium using standard clinical chemistry analyzers on fasting
serum samples taken at baseline. We measured urine
creatinine using the rate Jaff e method.
20 We measured urine
albumin using nephelometry, and indexed urine albumin to
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21 We measured cystatin C using a BNII
nephelometer (Siemens)–based particle-enhanced immuno-
nephelometric assay (N Latex Cystatin-C).
22 We calculated
estimated glomerular ﬁltration rate (eGFR) using the equation
eGFR=76.79(serum cystatin C)
1.
19,23
Statistical Analysis
We examined the distribution of the above-listed covariates by
quartile of FGF-23 and examined Spearman correlation
coefﬁcients. We evaluated dose-response relationships of
FGF-23 with LVMI and LVEF and used multivariable-adjusted
linear regression with least-square means
24 to estimate
adjusted LVMI and resting LVEF by quartile of FGF-23. After
ln-transforming FGF-23 because of its skewed distribution, we
used multivariable-adjusted linear regression to examine
continuous relationships per standard deviation (SD) of
lnFGF-23. Finally, we used multinomial logistic regression to
evaluate the simultaneous odds ratios of concentric or
eccentric hypertrophy compared with no hypertrophy. We
used multinomial logistic regression for this analysis, as these
forms of LVH were, by deﬁnition, mutually exclusive.
We derived 3 sequential models for multivariable linear and
logistic regression analyses. Model 1 adjusted for age, sex,
ethnicity, and BMI. Model 2 further adjusted for systolic blood
pressure, prevalent diabetes, prevalent hypertension, physical
activity score, current smoking status, pack-years, total
cholesterol (quintiles), high-density lipoprotein cholesterol
(log), and triglycerides (log). Model 3 in addition adjusted for
serum phosphorous and calcium, albumin-to-creatinine ratio
(ACR; log), and eGFR. Covariate forms were chosen after
graphical examination and comparison of model likelihood
statistics.
Given the strong prior hypothesis of effect modiﬁcation
by underlying kidney disease,
25 we performed analyses
stratiﬁed by the presence or absence of CKD, deﬁned as
estimated GFR <60 versus ≥60 mL/min per 1.73 m
2.W e
subsequently tested the multiplicative interaction of FGF-23
with CKD. We also conducted sensitivity analyses restricting
the range of FGF-23 to levels observed among patients with
normal kidney function (<350 RU/mL). We tested multipli-
cative interaction by sex and race, but no interactions were
observed.
We performed analyses using SAS software, version 9.2,
and Stata Statistical Software, version 10.1. P values <0.05
were considered statistically signiﬁcant.
Murine Experiments
We crossbred heterozygous klotho-null mice to obtain homo-
zygous klotho(/) and heterozygous klotho(/+) mutants.
We identiﬁed genotypes by polymerase chain reaction using
genomic DNA extracted from tail clips.
26 Klotho-deﬁcient mice
lack the klotho coreceptor required for FGF-23 to promote
phosphaturia in the kidney; as a result, they display signiﬁ-
cantly elevated circulating levels of FGF-23 accompanied by
soft-tissue and vascular calciﬁcations by 3–6 weeks of age.
26
Mice were fed with a standard diet ad libidum and maintained
in accordance with the US National Institutes of Health Guide
for the Care and Use of Laboratory Animals. All experimental
protocols were approved by the institutional care and use
committee at Harvard Medical School.
Cardiac MRI in Mice
We performed MRI on wild-type (n=4), klotho(/+)( n =5), and
klotho(/)( n =5) mice at 4 weeks of age. As positive
controls for LVH,
27 we also imaged 2 homozygous and 1
heterozygous 1-a hydroxylase–null mice.
We conducted MRI with a Bruker 9.4 Tesla Biospec 94/20
system (Bruker Instruments, Billerica, MA) using a quadrature
40-mm mouse body volume coil. We anesthetized animals
with 0.5% to 3% vaporized isoﬂurane and monitored ECG and
respiratory signals during imaging. We used a cardiac- and
respiratory-gated fast gradient echo sequence (FLASH-cine)
with the following parameters: 30-degree ﬂip angle; time to
echo, 2.8 ms; time to repeat, 20 ms; matrix size, 1929192;
ﬁeld of view, 25.6925.6 mm; and 4 averages. We acquired
contiguous image slices (1 mm thick) of the heart’s short axis
from the apex covering the heart’s full volume.
For each image slice, we manually traced the left
ventricular wall region and internal chamber region using
Image J software. We used the pixel-to-area conversion factor
1 pixel/0.018 mm
2 to estimate the left ventricular wall area,
left ventricular chamber area at systole, and left ventricular
chamber area at diastole. We multiplied the area measure-
ments by slice thickness to obtain volume measurements for
each slice and summed the volume measurements to
determine total volume.
28 We determined LVEF on the basis
of the estimated left ventricular chamber volume at systole
and diastole. After ln-transformation to achieve normality and
similar variances across genotypes, we compared left ven-
tricular wall volumes and ejection fractions between geno-
types using ANOVA. For left ventricular wall volume, we
adjusted our results for left ventricular internal chamber
volume to account for differences in mouse size.
Heart Weight and Histology
We obtained murine data on heart weight and histology in a
distinct set of mice to conﬁrm the results we obtained via
cardiac MRI. We anesthetized mice at 6 weeks of age and
perfused with 0.1 mol/L phosphate-buffered saline and ﬁxed
in 10% buffered formalin. We measured wet heart weight and
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determine the index of cardiac hypertrophy. After embedding
hearts in parafﬁn blocks, we cut 5-lm sections and stained
them with hematoxylin/eosin solution. Cross-sectional
images were documented using a DP controller and Manager
(Olympus Soft Imaging Solutions).
We determined heart weight/body weight ratio in wild-
type (n=6), klotho(/+)( n =5), and klotho(/)( n =12) mice.
After checking normality and similar variances, we compared
heart weight/body weight ratio between genotypes using
ANOVA.
We obtained 1 to 3 histological cross-sections at the
midventricular level of the heart from wild-type (n=4) and
klotho(/)( n =4) mice. Using Image J software, we manually
traced the total area of the LV in each section and compared
LV area in wild-type (n=4) and klotho(/)( n =4) mice using
generalized estimating equations with a Gaussian link and a
compound symmetry covariance structure to account for the
repeated sections within individual mice.
Results
Participant Characteristics
Compared with participants in the lowest quartile of FGF-23,
participants in the higher quartiles were more frequently
female, hypertensive, diabetic, and current smokers (Table 1).
Those in higher quartiles of FGF-23 were also less physically
active, had higher triglycerides, higher serum phosphorous,
higher ACR, and lower eGFR.
The participants included in these analyses had a broad
range of kidney function. In the entire study population, 167
participants had normal kidney function (eGFR ≥90 mL/min
per 1.73 m
2), 449 participants had eGFR between 60 and
90 mL/min per 1.73 m
2, and 271 participants had eGFR
<60 mL/min per 1.73 m
2.
FGF-23 concentrations varied markedly among patients
with different levels of kidney function. Median FGF-23 levels
were 32.3 RU/mL (interquartile range 26.7) in participants
Table 1. Characteristics of Heart and Soul Study Subjects by Quartile of FGF-23 (RU/mL)*
Variables
Quartile 1
(≤27.7),
n=222
Quartile 2
(27.8 to 43.0),
n=221
Quartile 3
(43.1 to 71.4),
n=222
Quartile 4
(≥71.5),
n=222
Age, y 66 (10) 67 (11) 67 (11) 67 (12)
Male, n (%) 193 (87) 187 (85) 182 (82) 167 (75)
White, n (%) 133 (60) 124 (56) 137 (62) 149 (67)
Blood pressure
Systolic, mm Hg 129 (19) 134 (22) 133 (20) 135 (23)
Comorbidities
Diabetes, n (%) 47 (21) 58 (26) 62 (28) 64 (29)
Hypertension, n (%) 140 (63) 160 (72) 160 (72) 163 (73)
Lifestyle factors
BMI, kg/m
2 27.9 (4.6) 28.2 (4.8) 28.9 (5.4) 28.4 (6.0)
Above average physical activity, n (%) 83 (37) 89 (40) 78 (35) 52 (23)
Current smoker, n (%) 36 (16) 35 (16) 38 (17) 68 (31)
Pack-years 20 (21) 19 (21) 20 (22) 24 (22)
Laboratory values
Total cholesterol, mg/dL 175 (40) 176 (38) 181 (43) 181 (49)
HDL-C, mg/dL 46 (13) 47 (13) 45 (14) 46 (16)
Triglycerides, mg/dL* 96 (66) 106 (92) 122 (90) 119 (109)
Serum phosphorous, mg/dL 3.5 (0.5) 3.6 (0.5) 3.7 (0.6) 3.8 (0.7)
Serum calcium, mg/dL 9.5 (0.5) 9.5 (0.5) 9.5 (0.5) 9.5 (0.6)
Renal function
Albumin-to-creatinine ratio ([ACR]91000) 30 (118) 33 (118) 53 (210) 146 (497)
eGFR, mL/min per 1.73 m
2 80 (18) 75 (19) 71 (24) 58 (21)
Mean (SD) for continuous variables except where speciﬁed; n (%) for dichotomous variables. BMI indicates body mass index; eGFR, estimated glomerular ﬁltration rate; FGF-23, ﬁbroblast
growth factor–23; HDL-C, high-density lipoprotein cholesterol.
*Median (interquartile range).
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Hwith normal kidney function, 39.1 RU/mL (interquartile range
30.8) among those with eGFR between 60 and 90 mL/min
per 1.73 m
2, and 68.5 RU/mL (interquartile range 90.2) in
participants with eGFR <60 mL/min per 1.73 m
2.
FGF-23, LVMI, and LVEF
In our crude model, FGF-23 was positively associated with
LVMI (Table 2). These results were attenuated and no longer
statistically signiﬁcant after adjustment for cardiovascular risk
factors, including serum phosphorous, serum calcium, ACR,
and eGFR. FGF-23 was inversely associated with LVEF in both
crude and multivariable-adjusted models, but with only a
modest decrease in LVEF across quartiles of FGF-23 (Table 2).
FGF-23 and Concentric and Eccentric
Hypertrophy
In multinomial logistic regression, FGF-23 was not statistically
signiﬁcantly associated with the prevalence of concentric
hypertrophy (odds ratio, 1.5; CI, 0.9 to 2.4 per SD increase in
lnFGF-23) or eccentric hypertrophy (odds ratio, 1.1; CI, 0.9 to
1.3) compared with no hypertrophy. The differential associ-
ations of FGF-23 with concentric versus eccentric hypertrophy
(with no hypertrophy as the referent) were not statistically
signiﬁcant (P=0.27).
Interactions With Kidney Function
In stratiﬁed analyses adjusting for eGFR as a continuous
variable (Table 3), FGF-23 was strongly related to concentric
hypertrophy in patients with eGFR <60 mL/min per 1.73 m
2
but not among patients with eGFR ≥60 mL/min per 1.73 m
2.
To determine if the greater association among participants
with CKD reﬂected their greater range in FGF-23 levels, we
performed analyses restricted to individuals with FGF-23
<350 RU/mL. Associations in this restricted population were
similar to our previous results. In the total population, kidney
function did not appear to modify the relationship between
FGF-23 and LVMI (P-interaction=0.87) or LVEF (P-interac-
tion=0.31).
Cardiac MRI in Mice
As expected, 1-a hydroxylase–deﬁcient mice used as positive
controls had signiﬁcantly greater wall volumes than did wild-
type mice (P=0.04). In contrast, klotho-deﬁcient mice did not
differ signiﬁcantly from wild-type mice (0.28 SD smaller ln-
tranformed wall volume in klotho-deﬁcient mice; CI ,0.87 to
0.32 SD; P=0.37). Similar to wild-type mice, klotho-deﬁcient
mice had signiﬁcantly lower wall volumes than 1-a hydroxy-
lase–deﬁcient mice (1.14 SD; CI, 2.13 to 0.14 SD;
P=0.02). Left ventricular function among klotho-deﬁcient mice
also did not differ signiﬁcantly from wild-type mice (0.04 SD
higher ln-transformed LVEF in klotho-deﬁcient mice; CI, 0.99
to 1.06 SD; P=0.94).
Heart Weight and Histology in Mice
No statistically signiﬁcant differences could be observed in
the heart weight/body weight ratio comparing wild-type,
klotho(/+), and klotho(/) mice (P=0.97; Figure) or in left
ventricular wall area measurements comparing wild-type and
klotho(/) mice (P=0.94).
Table 2. Least-Squares Mean Estimates of Left Ventricular Mass Index (g/m
2) and Left Ventricular Ejection Fraction (%) by
Quartile of FGF-23 (RU/mL)
Quartile 1
(≤27.7)
Quartile 2
(27.8 to 43.0)
Quartile 3
(43.1 to 71.4)
Quartile 4
(≥71.5)
Increase per
SD lnFGF-23 P Value
Left ventricular mass index, g/m
2
Model 1* 93.6 (90.2 to 96.9) 96.1 (92.7 to 99.4) 96.9 (93.6 to 100.3) 105.3 (101.9 to 108.7) 3.9 (0.9) <0.001
Model 2
† 94.6 (91.3 to 98.0) 96.3 (93.0 to 99.6) 97.1 (93.8 to 100.4) 104.7 (101.3 to 108.1) 3.1 (0.9) <0.001
Model 3
‡ 95.9 (92.5 to 99.3) 97.0 (93.7 to 100.3) 97.3 (94.0 to 100.6) 102.5 (99.0 to 106.1) 1.4 (1.0) 0.15
Left ventricular ejection fraction, %
Model 1* 62.9 (61.7 to 64.2) 62.5 (61.2 to 63.7) 62.2 (60.9 to 63.5) 59.3 (58.1 to 60.6) 1.3 (0.3) <0.001
Model 2
† 63.1 (61.8 to 64.4) 62.3 (61.0, 63.6) 62.3 (61.0 to 63.6) 59.2 (57.9 to 60.5) 1.3 (0.4) <0.001
Model 3
‡ 62.7 (61.4 to 64.0) 62.2 (60.9 to 63.5) 62.3 (61.0 to 63.6) 59.7 (58.3 to 61.1) 1.0 (0.4) 0.01
We provide least-squares mean estimates and conﬁdence intervals (by quartiles) and regression coefﬁcients and standard errors per SD lnFGF-23 (in the overall population). P values were
estimated by linear regression to test for trend. ACR indicates albumin-to-creatinine ratio; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; FGF-23, ﬁbroblast growth
factor–23; HDL, high-density lipoprotein; SBP, systolic blood pressure.
*Adjusted for age, sex, ethnicity, BMI.
†Adjusted for age, sex, ethnicity, BMI, SBP, diabetes, hypertension, physical activity score, smoking history, total cholesterol, HDL cholesterol, triglycerides.
‡Adjusted for age, sex, ethnicity, BMI, SBP, diabetes, hypertension, physical activity score, smoking history, total cholesterol, HDL cholesterol, triglycerides, serum phosphorous, serum
calcium, ACR, and eGFR.
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HDiscussion
Our study in a well-characterized population with stable
coronary artery disease and a broad range of kidney function
extends previously published evidence on the association
between circulating levels of FGF-23 and cardiac hypertrophy.
In 887 individuals enrolled in the Heart and Soul Study, FGF-
23 was not associated with left ventricular mass or odds of
concentric or eccentric hypertrophy. We observed a strong
association between FGF-23 and concentric hypertrophy only
among individuals with CKD. In our murine experiments, we
were unable to conﬁrm previous ﬁndings of LVH in klotho-
deﬁcient mice, an established animal model of elevated FGF-
23. Together, our results raise questions about the general-
izability of the effect of FGF-23 on cardiac structure and
suggest that further research is needed to prove a direct
effect of FGF-23 on the cardiovascular system in humans.
Although FGF-23 has been variably associated with
abnormal cardiac structure and function
3,6,8 and adverse
cardiovascular outcomes
7,25 in individuals with and without
CKD, ﬁndings have been inconsistent,
11 and when present,
associations have generally been stronger among individuals
with impaired renal function.
6,9 At present, it remains
controversial whether FGF-23 has a direct effect on the
cardiovascular system.
There are several possible mechanisms by which FGF-23
may affect cardiac structure and function indirectly. It is
possible that FGF23 provides an alternative measure of renal
impairment (imperfectly captured by eGFR or ACR) that can
indirectly lead to cardiovascular remodeling and adverse
events via hemodynamic overload and pressure and volume
expansion.
29 Alternatively, FGF-23 may be a marker of time-
averaged serum phosphorous and, by extension, vascular
calciﬁcation—a known risk factor for cardiovascular remod-
eling.
30 In this study, associations of FGF-23 with LVEF were
not signiﬁcantly attenuated by adjustment for serum phos-
phorous levels measured at a single time. Nonetheless, a
single serum phosphorus measurement may not accurately
represent cumulative phosphorus burden, given the high
intraindividual biological variability in serum phosphorus levels
when measured repeatedly over time.
31 Finally, FGF-23 may
affect the cardiovascular system indirectly by inducing
hypovitaminosis D via inhibition of 1a-hydroxylase, given the
large body of evidence for vitamin D deﬁciency as a
cardiovascular risk factor.
32
Although a direct effect of FGF-23 on the heart has been
hypothesized, evidence to support this hypothesis is lim-
ited.
12,14 In 1 murine experiment, intravenous or direct
injection of recombinant FGF-23 protein into the myocardium
resulted in LVH within 5 or 14 days, respectively.
12 However,
conﬁrmatory studies of LVH reduction by FGF-23 neutraliza-
tion
13 have produced mixed results. Faul et al reported that
klotho-deﬁcient mice, an established murine model of ele-
vated FGF-23, develop echocardiographic LVH
12—and inter-
preted this as evidence that FGF-23 action on cardiac tissue is
independent of the klotho coreceptor. Our study using cardiac
MRI, a potentially more accurate 3-dimensional imaging
modality than echocardiography, did not provide evidence of
LVH or diminished ejection fraction in klotho-deﬁcient mice.
Our MRI ﬁndings were substantiated by heart weight and
histological data, which also showed no signiﬁcant differences
between wild-type and klotho-deﬁcient mice.
Table 3. Estimated Odds Ratios and Conﬁdence Intervals Per Standard Deviation (SD) Increase in lnFGF-23, Stratiﬁed by Chronic
Kidney Disease (eGFR <60 mL/min per 1.73 m
2)
eGFR <60 mL/min per 1.73 m
2 eGFR ≥60 mL/min per 1.73 m
2
n=271 Odds Ratio P Value n=616 Odds Ratio P Value
No hypertrophy 87 1.0 (ref) — 305 1.0 (ref) —
Eccentric hypertrophy 171 1.0 (0.7 to 1.4) 0.93 300 1.1 (0.9 to 1.4) 0.37
Concentric hypertrophy 13 2.3 (1.0 to 5.3) 0.04 11 1.0 (0.4 to 2.5) 0.94
ACR indicates albumin-to-creatinine ratio; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; FGF-23, ﬁbroblast growth factor–23; HDL, high-density lipoprotein; SBP,
systolic blood pressure. Adjusted for age, sex, ethnicity, BMI, SBP, diabetes, hypertension, physical activity score, smoking history, total cholesterol, HDL cholesterol, triglycerides, serum
phosphorous, serum calcium, ACR, and eGFR. P-interaction=0.28.
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Figure. Heart weight/body weight ratio in wild-type (WT) (n=6),
klotho(/+)( n =5), and klotho(/)( n =12) mice at 6 weeks of age.
Values are expressed as mean  standard error (SE) for each group.
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results with those reported previously. First, mice in our
study were 4 to 6 weeks old, whereas klotho-deﬁcient mice
found to have echocardiographic LVH were 8 to 12 weeks
old at the time that cardiac size was assessed. It is possible
that differences in left ventricular size and systolic function
do not manifest at an early age, although klotho-deﬁcient
mice do display signiﬁcantly elevated circulating levels of
FGF-23 accompanied by soft-tissue and vascular calciﬁca-
tions as early as 3–6 weeks of age.
26 Another possible
explanation for our failure to detect LVH in klotho-deﬁcient
mice is our small sample sizes (n=5 to 6 mice/genotype),
although our sample sizes were similar to those in previous
studies that observed LVH and were sufﬁcient to observe
LVH in our positive controls. A ﬁnal possible explanation for
our ﬁndings is that the use of cardiac MRI, a potentially more
accurate imaging modality than echocardiography, reduced
measurement error in assessing cardiac size and produced
more accurate results. To validate our ﬁndings, further in
vitro and in vivo experimentation with direct injection of FGF-
23 and inhibition of the klotho coreceptor, ideally in murine
models with and without CKD at earlier and later ages, is
needed.
This study has several strengths. Few previous studies
have had the necessary data to examine whether FGF-23 is
associated with left ventricular mass and systolic dysfunc-
tion in patients without CKD. With 887 participants, we were
able to study the association of FGF-23 and cardiac
structure and function with precision. We adjusted for
important potential confounders not available in most
previous studies, including serum phosphorous and calcium,
ACR, and cystatin-based eGFR, though we cannot exclude
the possibility of residual confounding or confounding by
other unknown characteristics. FGF-23 was measured in
duplicate, with low intra- and interassay coefﬁcients of
variations. Echocardiograms were examined by a blinded
cardiologist before the FGF23 measurements were con-
ducted, reducing the likelihood of measurement error and
misclassiﬁcation bias.
Our study also has important limitations. As a result of our
cross-sectional study design, we are unable to determine
temporality. Because the participants in our study were
mostly white men with stable coronary heart disease, caution
must be taken in generalizing our results to other populations.
Furthermore, we did not have information on variables such
as erythropoietin levels or vasomotor responses in this cohort
study, which could have shed light on the observed associ-
ation among individuals with CKD.
Despite recent pharmacological advances, long-term out-
comes in patients with CKD remain poor. If the observed
relationships between elevated FGF-23 and LVH among
individuals with CKD are causal, it is tempting to speculate
that FGF-23 may become a therapeutic target in these
patients, and clinical trials are currently ongoing. However,
our results suggest that FGF-23 is unlikely to be a major
target among patients without underlying CKD.
In conclusion, we observed a modest association of FGF-
23 with worse left ventricular systolic function in the entire
population and an association of FGF-23 with LVMI and
concentric LVH only among individuals with CKD. Our murine
experiments found no evidence of LVH in klotho-deﬁcient
mice, using both cardiac MRI and histological analysis. Our
results suggest that FGF-23 is unlikely to have major direct
effects on cardiovascular structure and function among
patients free of substantial CKD; furthermore, if present,
any direct effect on the myocardium may not be independent
of the klotho coreceptor.
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